May 24, 2016
1 pm to 2 pm EDT

Sponsored by
MedGenome logo



Webinar Description:

Genomic approaches to model the immune landscape of human tumors for cancer immunotherapy. Cancer Immunotherapy, which uses the innate power of the immune system to fight cancer, has recently been demonstrated to offer significant clinical benefits for a number of challenging cancers. Using analytics one can analyze exome and RNA-seq data to quantitate the epithelial, stromal and immune cell infiltration and produce a holistic view of the tumor and the tumor microenvironment. By assessing the T-cell neo-epitope burden and the immune phenotype of the tumor, one can also identify novel drug targets and biomarkers of response to cancer immunotherapy drugs.

Learning Objectives:

  • Immune genotyping and phenotyping of the tumor microenvironment.
  • Characterization of the tumor mutanome, HLA typing and neo-epitope prioritization and validation.
  • Utilization of a knowledgebase of antigens built using TCGA data to prioritize neoepitopes quickly.


Amitabha ChaudhuriDr. Amitabha Chaudhuri, Ph.D.

VP-Research and Development

MedGenome Inc,

Dr. Amitabha Chaudhuri has over 15 years’ experience in oncology target discovery and validation at Genentech Inc, Inpharmatica Inc, and CuraGen Corporation. He holds a Ph.D. in Biochemistry from Indian Institute of Science, Bangalore and did his Post-Doctoral work at Massachusetts General Hospital, Harvard Medical School and at the Department of Molecular & Cellular Biology, Harvard University. His graduate and post-graduate research was to understand the molecular and biochemical basis of cell surface receptor signaling, cellular metabolism and establishment and maintenance of cellular polarity. He has co-authored several papers in Science and Nature.